Mineralocorticoid antagonism: A novel way to treat sarcopenia and physical impairment in older people?

Clinical Endocrinology

Volumn 75, Issue 6, 2011, Pages 725-729

  Burton, Louise A ^a   McMurdo, Marion E T ^a   Struthers, Allan D ^b  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ADENOSINE TRIPHOSPHATASE (MAGNESIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN II; INDUCIBLE NITRIC OXIDE SYNTHASE; MINERALOCORTICOID; NITRIC OXIDE; PLACEBO; SPIRONOLACTONE; TUMOR NECROSIS FACTOR ALPHA;

AGING; ALCOHOL LIVER CIRRHOSIS; APOPTOSIS; DRUG EFFECT; EXERCISE TOLERANCE; HEART FAILURE; HEART FUNCTION; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE CONTRACTILITY; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE METABOLISM; MUSCLE STRENGTH; NONHUMAN; OXIDATIVE STRESS; PHYSICAL DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

AGED; AGED, 80 AND OVER; AGING; ALDOSTERONE ANTAGONISTS; HUMANS; MOBILITY LIMITATION; MOTOR ACTIVITY; RECEPTORS, MINERALOCORTICOID; RESTRAINT, PHYSICAL; SARCOPENIA; SPIRONOLACTONE;

EID: 80855128819     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2011.04148.x     Document Type: Review

References (56)

1. Larsson, L., Grimby, G., &, Karlsson, J., (1979) Muscle strength and speed of movement in relation to age and muscle morphology. Journal of Applied Physiology, 46, 451-456. (Pubitemid 9163080)
2. Sayer, A.A., Syddall, H., Martin, H., et al. (2008) The developmental origins of sarcopenia. The Journal of Nutrition, Health and Aging, 12, 427-432.
3. Szulc, P., Munoz, F., Marchand, F., et al. (2010) Rapid loss of appendicular skeletal muscle mass is associated with higher all-cause mortality in older men: the prospective MINOS study. American Journal of Clinical Nutrition, 91, 1227-1236.
4. Sumukadas, D., Struthers, A.D., &, Mcmurdo, M.E.T., (2006) Sarcopenia-a potential target for angiotensin-converting enzyme inhibition? Gerontology, 52, 237-242. (Pubitemid 44114443)
5. Sumukadas, D., Witham, M.D., Struthers, A.D., et al. (2007) Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. Canadian Medical Association Journal, 177, 867-874. (Pubitemid 47612819)
6. Coggan, A.R., Abduljalil, A.M., Swanson, S.C., et al. (1993) Muscle metabolism during exercise in young and older untrained and endurance-trained men. Journal of Applied Physiology, 75, 2125-2133. (Pubitemid 23352386)
7. Lexell, J., (1995) Human aging, muscle mass, and fiber-type composition. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, 50, 11-16.
8. Warburton, D.E.R., Nicol, C.W., &, Bredin, S.S.D., (2006) Health benefits of physical activity: the evidence. Canadian Medical Association Journal, 174, 801-809.
9. Erim, Z., Beg, M.F., Burke, D.T., et al. (1999) Effects of aging on motor-unit control properties. Journal of Neurophysiology, 82, 2081-2091.
10. Goya, R.G., Brown, O.A., &, Bolognani, F., (1999) The thymus-pituitary axis and its changes during aging. Neuroimmunomodulation, 6, 137-142. (Pubitemid 29049167)
11. Koopman, R., &, van Loon, L.J.C., (2009) Aging, exercise, and muscle protein metabolism. Journal of Applied Physiology, 106, 2040-2048.
12. Narayanan, N., Jones, D.L., Xu, A., et al. (1996) Effects of aging on sarcoplasmic reticulum function and contraction duration in skeletal muscles of the rat. American Journal of Physiology. Cell Physiology, 40, C1032-C1040.
13. Delbono, O., (1992) Calcium current activation and charge movement in denervated mammalian skeletal-muscle fibers. The Journal of Physiology-London, 451, 187-203.
14. Conley, K.E., Jubrias, S.A., &, Esselman, P.C., (2000) Oxidative capacity and ageing in human muscle. The Journal of Physiology-London, 526, 203-210. (Pubitemid 30456102)
15. Funder, J.W., (2004) Aldosterone, mineralocorticoid receptors and vascular inflammation. Molecular and Cellular Endocrinology, 217, 263-269. (Pubitemid 38596652)
16. Silvestre, J.S., Robert, V., Heymes, C., et al. (1998) Myocardial production of aldosterone and corticosterone in the rat-physiological regulation. The Journal of Biological Chemistry, 273, 4883-4891. (Pubitemid 28108638)
17. Rocha, R., Stier, C.T., Kifor, I., et al. (2000) Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology, 141, 3871-3878.
18. Swedberg, K., Eneroth, P., Kjekshus, J., et al. (1990) Hormones regulating cardiovascular function in patients with severe congestive-heart- failure and their relation to mortality. Circulation, 82, 1730-1736. (Pubitemid 20367976)
19. Macdonald, J.E., Kennedy, N., &, Struthers, A.D., (2004) Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart, 90, 765-770. (Pubitemid 38813637)
20. Burniston, J.G., Saini, A., Tan, L.B., et al. (2005) Aldosterone induces myocyte apoptosis in the heart and skeletal muscles of rats in vivo. Journal of Molecular and Cellular Cardiology, 39, 395-399. (Pubitemid 40995029)
21. McKelvie, R.S., Yusuf, S., Pericak, D., et al. (1999) Comparison of candesartan, enalapril, and their combination in congestive heart failure-Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study-The RESOLVD pilot study investigators. Circulation, 100, 1056-1064. (Pubitemid 29416231)
22. Hutcheon, S.D., Gillespie, N.D., Crombie, I.K., et al. (2002) Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial. Heart, 88, 373-377.
23. Cicoira, M., Zanolla, L., Franceschini, L., et al. (2002) Relation of aldosterone "escape" despite angiotensin-converting enzyme inhibitor administration to impaired exercise capacity in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. American Journal of Cardiology, 89, 403-407. (Pubitemid 34142514)
24. Cicoira, M., Zanolla, L., Rossi, A., et al. (2002) Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in chronic heart failure patients. European Heart Journal, 23, 28.
25. Koch, D.W., Newcomer, S.C., &, Proctor, D.N., (2005) Blood flow to exercising limbs varies with age, gender, and training status. Canadian Journal of Applied Physiology-Revue Canadienne de Physiologie Appliquee, 30, 554-575.
26. Marechal, G., &, Gailly, P., (1999) Effects of nitric oxide on the contraction of skeletal muscle. Cellular and Molecular Life Sciences, 55, 1088-1102. (Pubitemid 29361075)
27. Grozdanovic, Z., (2001) NO message from muscle. Microscopy Research and Technique, 55, 148-153. (Pubitemid 33029627)
28. Rajagopalan, S., Duquaine, D., King, S., et al. (2002) Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation, 105, 2212-2216. (Pubitemid 34517167)
29. Leopold, J.A., Dam, A., Maron, B.A., et al. (2007) Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nature Medicine, 13, 189-197.
30. Bauersachs, J., Heck, M., Fraccarollo, D., et al. (2002) Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction-role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. Journal of the American College of Cardiology, 39, 351-358. (Pubitemid 34084645)
31. Farquharson, C.A.J., &, Struthers, A.D., (2000) Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation, 101, 594-597. (Pubitemid 30094728)
32. Clement, D.L., (1982) Effect of spironolactone on systemic blood-pressure, limb blood-flow and response to sympathetic-stimulation in hypertensive patients. European Journal of Clinical Pharmacology, 21, 263-267. (Pubitemid 12248761)
33. Swaminathan, K., Davies, J., George, J., et al. (2008) Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia, 51, 762-768.
34. Bendtzen, K., Hansen, P.R., &, Rieneck, K., (2003) Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis. Clinical and Experimental Immunology, 134, 151-158. (Pubitemid 37186601)
35. Dirks, A.J., &, Leeuwenburgh, C., (2006) Tumor necrosis factor alpha signaling in skeletal muscle: effects of age and caloric restriction. The Journal of Nutritional Biochemistry, 17, 501-508. (Pubitemid 44102706)
36. Narula, J., Haider, N., Virmani, R., et al. (1996) Apoptosis in myocytes in end-stage heart failure. New England Journal of Medicine, 335, 1182-1189. (Pubitemid 26339772)
37. Adams, V., Jiang, H., Yu, J.T., et al. (1999) Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. Journal of the American College of Cardiology, 33, 959-965.
38. Anker, S.D., Chua, T.P., Ponikowski, P., et al. (1997) Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation, 96, 526-534. (Pubitemid 27329429)
39. Braga, M., Hikim, A.P.S., Datta, S., et al. (2008) Involvement of oxidative stress and caspase 2-mediated intrinsic pathway signaling in age-related increase in muscle cell apoptosis in mice. Apoptosis, 13, 822-832.
40. Dyckner, T., &, Wester, P.O., (1979) Ventricular extra-systoles and intracellular electrolytes before and after potassium and magnesium infusions in patients on diuretic treatment. American Heart Journal, 97, 12-18. (Pubitemid 9089790)
41. Gullestad, L., Dolva, L.O., Soyland, E., et al. (1992) Oral magnesium supplementation improves metabolic variables and muscle strength in alcoholics. Alcoholism, Clinical and Experimental Research, 16, 986-990.
42. Aagaard, N.K., Andersen, H., Vilstrup, H., et al. (2002) Muscle strength, Na, K-pumps, magnesium and potassium in patients with alcoholic liver cirrhosis-relation to spironolactone. Journal of Internal Medicine, 252, 56-63. (Pubitemid 34746036)
43. Aagaard, N.K., Andersen, H., Vilstrup, H., et al. (2003) Decreased muscle strength and contents of Mg and Na, K-pumps in chronic alcoholics occur independently of liver cirrhosis. Journal of Internal Medicine, 253, 359-366. (Pubitemid 36315208)
44. + pump regulation and skeletal muscle contractility. Physiological Reviews, 83, 1269-1324. (Pubitemid 37222273)
45. Lastra, G., Whaley-Connell, A., Manrique, C., et al. (2008) Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. American Journal of Physiology. Endocrinology and Metabolism, 295, E110-E116.
46. Vescovo, G., Dalla Libera, L., Serafini, F., et al. (1998) Improved exercise tolerance after losartan and enalapril in heart failure-Correlation with changes in skeletal muscle myosin heavy chain composition. Circulation, 98, 1742-1749. (Pubitemid 28492494)
47. Hernandez, N., Torres, S.H., Finol, H.J., et al. (1996) Capillary and muscle fiber type changes in DOCA-salt hypertensive rats. The Anatomical Record, 246, 208-216. (Pubitemid 26338904)
48. Cicoira, M., Zanolla, L., Rossi, A., et al. (2001) Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. Journal of the American College of Cardiology, 37, 1808-1812. (Pubitemid 32499963)
49. Morgan, S., Smith, H., Simpson, I., et al. (1999) Prevalence and clinical characteristics of left ventricular dysfunction among elderly patients in general practice setting: cross sectional survey. British Medical Journal, 318, 368-372. (Pubitemid 29192086)
50. Daniel, K.R., Wells, G., Stewart, K., et al. (2009) Effect of aldosterone antagonism on exercise tolerance, Doppler diastolic function, and quality of life in older women with diastolic heart failure. Congestive Heart Failure, 15, 68-74.
51. Weber, K.T., &, Brilla, C.G., (1991) Pathological hypertrophy and cardiac interstitium-fibrosis and renin-angiotensin-aldosterone system. Circulation, 83, 1849-1865.
52. De Angelis, N., Fiordaliso, J., Latini, R., et al. (2002) Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. Journal of Molecular and Cellular Cardiology, 34, 1655-1665. (Pubitemid 35454480)
53. Dyckner, T., Wester, P.O., &, Widman, L., (1986) Effects of spironolactone on serum and muscle electrolytes in patients on long-term diuretic therapy for congestive-heart-failure and or arterial-hypertension. European Journal of Clinical Pharmacology, 30, 535-540. (Pubitemid 16073886)
54. Hensen, J., Abraham, W.T., Durr, J.A., et al. (1991) Aldosterone in congestive-heart-failure-analysis of determinants and role in sodium retention. American Journal of Nephrology, 11, 441-446.
55. Mizuno, Y., Yoshimura, M., Yasue, H., et al. (2001) Aldosterone production is activated in failing ventricle in humans. Circulation, 103, 72-77. (Pubitemid 32050438)
56. Pitt, B., Zannad, F., Remme, W.J., et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine, 341, 709-717. (Pubitemid 29407370)